SCHEMBL4664598

SCHEMBL4664598

N#Cc1cc2c(Cl)ccnc2cc1OCCCn1ccnn1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 10/20 0.54
PDGFRB P09619 4/20 0.41
FGFR1 P11362 3/20 0.40
FLT1 P17948 3/20 0.40
FGFR2 P21802 3/20 0.40
FGFR4 P22455 3/20 0.40
FGFR3 P22607 3/20 0.40
FLT4 P35916 3/20 0.40
KDR P35968 3/20 0.40
FYN P06241 3/20 0.36
WEE2 P0C1S8 2/20 0.36
WEE1 P30291 2/20 0.36
PKMYT1 Q99640 2/20 0.36
EHMT2 Q96KQ7 2/20 0.36
EHMT1 Q9H9B1 2/20 0.36
CYP19A1 P11511 1/20 0.36
MAP2K1 Q02750 2/20 0.36
IGF1R P08069 1/20 0.36
ABL1 P00519 2/20 0.35
BCR P11274 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4665960 0.95 SRC (0.49) SRCPDGFRBFGFR1FLT1FGFR2
SCHEMBL4664563 0.81 EHMT2 (0.52) SRCPDGFRBFYNWEE2WEE1
SCHEMBL4664106 0.79 WEE2 (0.54) SRCPDGFRBFLT1KDRFYN
SCHEMBL6464138 0.78 SRC (0.57) SRCFYNMAP2K1IGF1RABL1
SCHEMBL1893907 0.77 SRC (0.51) SRCFGFR1FLT1FGFR4KDR
SCHEMBL4664567 0.76 SRC (0.45) SRCPDGFRBFYNWEE2WEE1
Hydrochloric Acid SCHEMBL6433816 0.76 SRC (0.50) SRCFGFR1FLT1FGFR4KDR
SCHEMBL4665978 0.75 SRC (0.38) SRC
SCHEMBL4664094 0.75 KDR (0.52) SRCPDGFRBFGFR1FLT1FGFR2
SCHEMBL2178127 0.74 PDGFRA (0.57) PDGFRBFLT4KDRCSF1RMET

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity HENNEQUIN LAURENT FRANCOIS ANDRE 2008-12-18 US disclosed
US-7371765-B2 Quinoline derivatives having VEGF inhibiting activity ASTRAZENECA AB (SE) 2008-05-13 US disclosed
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity ASTRAZENECA AB (SE) 2003-10-23 US disclosed
EP-1313726-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY AstraZeneca AB (SE) 2003-05-28 EP disclosed
WO-2002012226-A1 QUINOLINE DERIVATIVES HAVING VEGF INHIBITING ACTIVITY ASTRAZENECA AB (SE) 2002-02-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312273-A1 Quinoline Derivatives Having Vegf Inhibiting Activity VEGFA, FLT1, FLT4 SRC 1933/4885PDGFRB 282/4885FGFR1 99/4885
US-20030199491-A1 Quinoline derivatives having vegf inhibiting activity VEGFA, FLT1, FLT4 SRC 3356/4885PDGFRB 206/4885FGFR1 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.